After hearing feedback and to further ease the transition burden on researchers and ERIK team members, two data migrations will take place.
Any pending new study, amendment or continuing review submissions (e.g., incomplete, modifications required, deferred) in Buck-IRB will not be migrated into the Huron system. To allow time to complete screening IRB/exempt reviews in Buck-IRB and minimize the disruption to operations, migration will occur in two phases targeted for March 4 and March 21. The following are suggested dates to optimize chances for approval before the final migration - following these guidelines will help reduce the chances of starting the application process in Buck-IRB and missing the window for review, necessitating the need to submit the same application in Huron.
Julie Johnson, PharmD, is the Director and Principal Investigator at The Ohio State University Clinical and Translational Science Institute.